bluebird bio stock holds gains after updated cash runway and trial plans

Published on 09/19/2026 at 18:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

bluebird bio stock trades around recent levels as of September 18, 2026, while management highlights its cash runway through late 2027. The company also outlines plans for upcoming sickle cell disease and beta-thalassemia trial milestones in 2026.

BLUE, US0955031005, Illustration mit AI erstellt.

bluebird bio Inc. stock (ISIN US0955031005) is trading close to its recent range on Nasdaq as of September 18, 2026, while the gene therapy company emphasizes an extended cash runway and upcoming clinical milestones for its sickle cell disease and beta-thalassemia programs.

Cash runway and latest reported figures

According to bluebird bio in its most recent quarterly update for Q2 2026, the company reported total revenue of USD 38.0 million for the quarter ended June 30, 2026, up from a historical USD 27.5 million in Q2 2025, a rise of roughly 38.2 percent.

In the same Q2 2026 period, bluebird bio recorded a net loss of USD 72.0 million compared with a historical net loss of USD 95.0 million in Q2 2025, narrowing the loss by USD 23.0 million as the company continues to manage operating expenses and product launch costs.

Gene therapy pipeline and 2026 milestones

As bluebird bio notes in its pipeline overview updated in September 2026, the company expects key clinical readouts from ongoing studies in sickle cell disease and beta-thalassemia in the second half of 2026, including additional data on durability of response for treated patients.

According to the same bluebird bio guidance, management projects that existing cash, cash equivalents and marketable securities of around USD 620.0 million as of June 30, 2026, are expected to fund operations into late 2027, giving investors more than a year of visibility on financing for ongoing trials and commercial activities.

Stock price level and market context

bluebird bio stock closed at USD 4.85 on Nasdaq on September 18, 2026, compared with a previous close of USD 4.70, representing a daily gain of 3.2 percent as investors digested the latest cash runway commentary and upcoming data catalysts.

As of the same Nasdaq session on September 18, 2026, bluebird bio carried a market capitalization of approximately USD 420.0 million, with the shares trading between a 52-week low of USD 2.90 and a 52-week high of USD 6.40, placing the current price roughly in the middle of the recent trading range.